AU2024200344B2 — Polymorphs of sepiapterin and salts thereof
Assigned to PTC Therapeutics MP Inc · Expires 2025-11-06 · 1y expired
What this patent protects
Disclosed herein are solid forms of sepiapterin free base, including an amorphous solid form and polymorphic forms of sepiapterin free base. Further disclosed are crystalline polymorphic forms of sepiapterin salts, particularly sepiapterin hydrochloride salt. This data, for appli…
USPTO Abstract
Disclosed herein are solid forms of sepiapterin free base, including an amorphous solid form and polymorphic forms of sepiapterin free base. Further disclosed are crystalline polymorphic forms of sepiapterin salts, particularly sepiapterin hydrochloride salt. This data, for application number 2022203481, is current as of 2024-01-17 21:00 AEST
Drugs covered by this patent
- Sephience (SEPIAPTERIN) · Ptc Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.